Please login to the form below

Not currently logged in
Email:
Password:

Ogilvy Brussels names new associate director

Barbara Malengreaux will lead the consumer and health practice

Ogilvy-Brussels,-Barbara-Malengreaux

Ogilvy Public Relations Brussels has promoted Barbara Malengreaux to associate director and head of the consumer and health practice.

She has nine years of health and consumer marketing experience at Ogilvy Group Brussels, which has included communications support for product launches, health promotion and disease awareness campaigns.

During her time with the group, she supported Pfizer with the design and implementation of the integrated 'Siga red' campaign, for smoking cessation, and she managed the 'Lights out' campaign for the Belgian Pharmacists Association (APB).

The new role will involve Malengreaux working on other-the-counter (OTC) and prescription brands, targeting consumers/patients, healthcare professionals (HCP) and stakeholders.

"We are delighted that Barbara will be bringing her considerable experience to this role to build on our strong heritage and proven track record in delivering creative and award winning consumer and health campaigns," said Ogilvy Group Brussels CEO, Koen Van Impe.

"Barbara will be an essential member of our senior team working to continue the growth and success of the team in Brussels," he added.

Commenting on her promotion, Malengreaux said: "I am very excited about the opportunity to lead the Consumer and Health practice.

"The PR approach combined with the Ogilvy group offering is ideally designed to help brands communicate their vision and values and build a deeper relationship with their key stakeholders."

15th March 2013

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...